Surge technology predicts post-surgical complications
PARIS, September 22, 2022 /PRNewswire/ — Surge announces a €2.5 million fundraising round, led by HCVC, a French-American fund dedicated to technology start-ups. Boutique Venture, US fund and several experienced business angels such as Nicholas GodinCOO/CFO of Cardiologs, also participated in the funding round, supplemented by grants such as the iLab grant, of which Surge is the winner in 2022. Surge is housed within the Agoranov incubator and benefits from the support of all 50 partners, Wilco and StartX in the United States.
Surge’s flagship product uses machine learning algorithms to decode a patient’s immune system from a blood sample. This technology allows clinicians to quickly predict the risk of postoperative complications. With 30% of major surgeries currently resulting in complications and 40% of patients over the age of 65 experiencing lasting cognitive impacts after orthopedic or cardiac surgery, Surge’s solution enables targeted and personalized interventions to reduce the risk of post-surgical complications for patients.
A proprietary solution developed between the United States and the France
Combining biological analysis of the immune system with an artificial intelligence algorithm, Surge can calculate the probability that a patient will develop a surgical complication. Depending on the test result, preventive management strategies can be proposed. The goal is to optimize the course of care to reduce the risk of postoperative complications.
Exclusive license and research agreement with the University of Stanford
In 2022, Surge got Stanford an exclusive, worldwide patent license to predict postoperative complications developed from more than ten years of surgical risk prediction research by Brice Gaudillière, MD, PhD, physician-researcher and associate professor of anesthesiology, perioperative medicine and pain in the Faculty of Medicine of the University of Stanford. This relationship between the prestigious university and Surge was reinforced in the summer of 2022 with the signing of a research agreement whose objective is, in particular, to develop biomedical innovation.
The fundraising will allow Surge to reinforce its teams to accelerate the development of its products and conduct clinical studies, such as the one that began in the spring of 2022 with the Foch de Suresnes Hospital.
View original content to download media:https://www.prnewswire.com/en/press-releases/surge-raises-2-5-million-euros-and-announces-exclusive-license-signing-with-stanford-301631472. html